EVFM — Evofem Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $0.71m
- $48.57m
- $18.22m
- 10
- 100
- 9
- 34
Annual cashflow statement for Evofem Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -80 | -142 | -205 | -76.7 | 53 |
| Depreciation | |||||
| Non-Cash Items | 37.3 | 52.4 | 46.9 | -0.745 | -67.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -12.7 | -15.2 | 10.6 | 6.02 | 4.73 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -55.1 | -105 | -147 | -70.4 | -8.97 |
| Capital Expenditures | -0.164 | -2.25 | -2.94 | -0.341 | -0.004 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -7.95 | 8.48 | 0.25 | 0 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -8.12 | 6.23 | -2.69 | -0.341 | -0.004 |
| Financing Cash Flow Items | -2.85 | -3.74 | -1.3 | -1.22 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 78.1 | 154 | 90.7 | 61.9 | 4.78 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 14.9 | 55.6 | -58.7 | -8.81 | -4.2 |